Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Inside your cells, these essential elements contain specific instructions – and that’s why they’re the target of 21st century…
Watch a short video about the patient journey, including gene therapy.
CSL Behring leaders are helping shape the conversation in Europe about how to give patients access to potentially game-changi…
CSL’s Debbie Drane recently spoke on a panel about how to keep momentum going following a record-setting year for cell and ge…
Working in cell transplantation, she’s motivated by “the true and genuine focus of delivering CSL’s promise to patients.”
As more gene therapy treatments are approved, this framework can help patients work with their doctors to make decisions abou…
Experts discussed health equity and access to gene and cell therapy at an event at the U.S. National Institutes of Health.
Gene therapies have the potential to transform a patient’s quality of life. But how will a complex network of stakeholders fi…
In episode 5, hear from Yann Le Cam, leader of Europe’s rare disease community, EURORDIS. In episode 6, experts explore the p…
Gene therapy marks a new era in the battle against genetic diseases. Learn more in a short video.
Debbie Drane, Senior Vice President of Commercial Development, moderates a panel on patient access to innovative treatments l…
More than 100 years ago, scientists started unlocking the mysteries of genes and inherited traits. Today, gene therapy holds …
Americas
Asia Pacific
Middle East
Europe
.jpg?h=900&iar=0&w=1600&cropregion=0,0,1600,900&hash=AD26B2F66451CD35F1240811CE5F28FD)